Cardiovascular Research Presents Mixed Outcomes at AHA Sessions

New findings from the American Heart Association's Scientific Sessions 2026 show varied results in cardiovascular trials. While ziltivekimab and pelacarsen did not reduce major cardiovascular events despite lowering target levels, spironolactone-based therapy significantly decreased home systolic blood pressure. These outcomes contribute to the ongoing understanding of cardiovascular disease management.